Huang Y, Ji Y, Yang X, Zhao Q, et al. Post-Treatment NLR and SII Associations with Response and Progression-Free Survival After Neoadjuvant Disitamab Vedotin Plus PD-1 Blockade in Muscle-Invasive Bladder Cancer: A Real-World Cohort Study. Diagnostics (Basel) 2026;16:2802.
PMID: 42739232